Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KELLEY WILSON

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1932398757
CMS profile
224261
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$65.09

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $65.09 3

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Regeneron Healthcare Solutions, Inc. $34.87 1
DERMIRA, INC. $30.22 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KELLEY WILSON

NPI 1932398757 · CMS profile ID 224261

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932398757?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932398757?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932398757?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
KELLEY WILSON, NPI 1932398757, CMS profile ID 224261, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1932398757?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $65.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $34.8711/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724466913 CMS
DERMIRA, INC. $14.6110/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736896504 CMS
DERMIRA, INC. $15.6107/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736900533 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,773.33 11
PY2020 $65.09 3
PY2021 $268.69 10
PY2022 $389.28 8
PY2023 $1,820.04 73
PY2024 $683.61 29
PY2025 $717.46 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,698,890.20 111
PY2024 Principal investigator $3,248,583.50 103
PY2023 Recipient $1,039.86 1
PY2023 Principal investigator $1,084,081.62 189
PY2022 Recipient $1,428.00 1
PY2022 Principal investigator $532,395.28 190
PY2021 Recipient $1,678.03 1
PY2021 Principal investigator $1,711,588.07 233
PY2020 Principal investigator $1,081,919.61 115
PY2019 Principal investigator $698,002.09 160

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

115 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $2,403.96 12/31/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721315977
Principal investigator 1 AbbVie Inc. $1,940.51 12/30/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721202763
Principal investigator 1 Avanir Pharmaceuticals, Inc. $2,500.00 12/22/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-303 No dispute reported 06/30/2026 775283683
Principal investigator 1 AbbVie Inc. $500.00 12/21/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721201417
Principal investigator 1 AbbVie Inc. $2,267.24 12/21/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721201419
Principal investigator 1 Incyte Corporation $26,905.69 12/18/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744310803
Principal investigator 1 Incyte Corporation $874.13 12/18/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 744310805
Principal investigator 1 Incyte Corporation $22,478.85 12/18/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 744310807
Principal investigator 1 PFIZER INC. $11,422.11 12/16/2020 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742898425
Principal investigator 1 Allergan, Inc. $12,336.70 12/15/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721312485
Principal investigator 1 Allergan, Inc. $2,500.00 12/14/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721311705
Principal investigator 1 Incyte Corporation $564.30 12/11/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744310799
Principal investigator 1 Incyte Corporation $2,545.00 12/11/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 744310801
Principal investigator 1 PFIZER INC. $8,434.13 12/02/2020 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742898363
Principal investigator 1 AbbVie Inc. $6,928.93 11/30/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721197209
Principal investigator 1 Incyte Corporation $66,566.48 11/27/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 744310787
Principal investigator 1 Incyte Corporation $17,439.17 11/27/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744310793
Principal investigator 1 Incyte Corporation $471.50 11/24/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744321647
Principal investigator 1 PFIZER INC. $3,415.50 11/20/2020 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742921885
Principal investigator 1 AbbVie Inc. $3,825.00 11/12/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721195131
Principal investigator 1 Incyte Corporation $695.50 11/06/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 744310785
Principal investigator 1 Incyte Corporation $2,762.55 11/06/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744310791
Principal investigator 1 Janssen Research & Development, LLC $3,473.00 11/05/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719483763
Principal investigator 1 Incyte Corporation $11,400.00 11/03/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 744310783
Principal investigator 1 Incyte Corporation $19,529.54 11/03/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744310789
Principal investigator 1 Incyte Corporation $11,400.00 11/03/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 744310797
Principal investigator 1 Janssen Research & Development, LLC $4,115.00 10/29/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719483761
Principal investigator 1 PFIZER INC. $3,893.06 10/29/2020 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742917623
Principal investigator 1 Incyte Corporation $3,441.16 10/27/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744321645
Principal investigator 1 Janssen Research & Development, LLC $1,056.00 10/19/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719483753
Principal investigator 1 PFIZER INC. $8,776.69 10/16/2020 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742921889
Principal investigator 1 GW Research Limited $12,025.00 10/14/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
GWAP19030 No dispute reported 06/30/2026 750016907
Principal investigator 1 Eli Lilly and Company $5,000.00 10/09/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 728729833
Principal investigator 1 Incyte Corporation $1,795.00 10/09/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 744310795
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 10/06/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY DBA OLYMPIAN CLINICAL RESEARCH
A 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF SOLRIAMFETOL [(R)-2-AMINO-3-PHENYLPROPYLCARBAMATE HYDROCHLORIDE] TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEP No dispute reported 06/30/2026 744484181
Principal investigator 1 Janssen Research & Development, LLC $4,244.00 10/05/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719483757
Principal investigator 1 PFIZER INC. $12,020.07 10/01/2020 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742921591
Principal investigator 1 AbbVie Inc. $1,322.18 09/30/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721188171
Principal investigator 1 Incyte Corporation $21,481.92 09/25/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744310779
Principal investigator 1 AbbVie Inc. $4,500.00 09/17/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721186225
Principal investigator 1 Allergan, Inc. $371.00 09/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721298023
Principal investigator 1 Allergan, Inc. $86.00 09/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721298111
Principal investigator 1 Incyte Corporation $8,129.05 09/17/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744321633
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 09/04/2020 Non-covered Recipient Entity
CLINTRAX GLOBAL INC
BIOANALYSIS OF JZP-110 (SOLRIAMTETOL) IN HUMAN PLASMA BY LC-MS/MS IN SUPPORT OF PROTOCOL JZP188-301 No dispute reported 06/30/2026 744485359
Principal investigator 1 Allergan, Inc. $700.00 09/01/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721294241
Principal investigator 1 Incyte Corporation $30,086.29 09/01/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744310777
Principal investigator 1 AbbVie Inc. $7,217.90 08/28/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721182989
Principal investigator 1 Allergan, Inc. $1,000.00 08/25/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721293419
Principal investigator 1 Allergan, Inc. $315.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721292313
Principal investigator 1 Allergan, Inc. $371.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721292499
Principal investigator 1 Incyte Corporation $41,930.39 08/03/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744310773
Principal investigator 1 AbbVie Inc. $1,905.06 07/30/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721177667
Principal investigator 1 Incyte Corporation $5,000.00 07/24/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744321639
Principal investigator 1 AbbVie Inc. $118.60 07/23/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721176535
Principal investigator 1 Incyte Corporation $13,377.21 07/21/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310759
Principal investigator 1 PFIZER INC. $8,795.00 07/16/2020 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742946643
Principal investigator 1 Incyte Corporation $450.00 07/14/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310757
Principal investigator 1 Avanir Pharmaceuticals, Inc. $1,143.84 07/09/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-303 No dispute reported 06/30/2026 722220231
Principal investigator 1 AbbVie Inc. $4,022.83 07/06/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721174773
Principal investigator 1 PFIZER INC. $70.00 07/02/2020 Non-covered Recipient Entity
Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742879719
Principal investigator 1 Incyte Corporation $400.00 07/01/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310761
Principal investigator 1 Incyte Corporation $2,497.75 07/01/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744321637
Principal investigator 1 Incyte Corporation $6,339.61 06/25/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310751
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 06/19/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 719483749
Principal investigator 1 Eisai Inc. $11,009.10 06/16/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749134287
Principal investigator 1 AbbVie Inc. $242.60 06/10/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721170627
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $825.00 06/10/2020 Non-covered Recipient Entity
CLINTRAX GLOBAL INC
BIOANALYSIS OF JZP-110 (SOLRIAMTETOL) IN HUMAN PLASMA BY LC-MS/MS IN SUPPORT OF PROTOCOL JZP188-301 No dispute reported 06/30/2026 744485247
Principal investigator 1 Incyte Corporation $1,200.00 06/04/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310749
Principal investigator 1 AbbVie Inc. $7,871.82 06/01/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721169331
Principal investigator 1 Incyte Corporation $26,332.33 06/01/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 744310763
Principal investigator 1 Incyte Corporation $16,866.95 05/19/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310745
Principal investigator 1 AbbVie Inc. $1,162.50 05/14/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721165973
Principal investigator 1 Incyte Corporation $1,250.00 05/12/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310743
Principal investigator 1 Incyte Corporation $12,726.24 05/07/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310739
Principal investigator 1 Incyte Corporation $5,000.00 05/07/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310741
Principal investigator 1 AbbVie Inc. $1,322.18 04/30/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721163369
Principal investigator 1 Allergan, Inc. $9,142.80 04/22/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721271857
Principal investigator 1 PFIZER INC. $8,795.00 04/18/2020 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742964871
Principal investigator 1 Incyte Corporation $11,117.39 04/16/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310705
Principal investigator 1 Allergan, Inc. $450.00 04/14/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721269477
Principal investigator 1 Allergan, Inc. $400.00 04/14/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721269665
Principal investigator 1 AbbVie Inc. $5,678.69 03/30/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721157967
Principal investigator 1 Incyte Corporation $19,469.05 03/26/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310689
Principal investigator 1 Janssen Research & Development, LLC $7,200.00 03/23/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719483739
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $20,217.30 03/23/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. No dispute reported 06/30/2026 748804261
Principal investigator 1 Allergan, Inc. $304.00 03/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721264917
Principal investigator 1 Eisai Inc. $1,000.00 03/17/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133551
Principal investigator 1 Janssen Research & Development, LLC $1,300.00 03/02/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics No dispute reported 06/30/2026 719483731
Principal investigator 1 AbbVie Inc. $1,281.48 02/28/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721152915
Principal investigator 1 Allergan, Inc. $86.00 02/27/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721261033
Principal investigator 1 Avanir Pharmaceuticals, Inc. $5,381.32 02/27/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-303 No dispute reported 06/30/2026 722219835
Principal investigator 1 Incyte Corporation $950.00 02/25/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310685
Principal investigator 1 Incyte Corporation $200.00 02/25/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310687
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $36,641.39 02/24/2020 Non-covered Recipient Entity
Olympian Clinical Research - South Tampa Office
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 736761457
Principal investigator 1 Janssen Research & Development, LLC $3,956.00 02/24/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719483745
Principal investigator 1 Incyte Corporation $300.00 02/20/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310679
Principal investigator 1 Incyte Corporation $19,196.01 02/20/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310681
Principal investigator 1 Incyte Corporation $1,550.00 02/20/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744310683
Principal investigator 1 Avanir Pharmaceuticals, Inc. $5,784.00 02/07/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
17-AVP-786-305 No dispute reported 06/30/2026 722219745
Principal investigator 1 Janssen Research & Development, LLC $340.00 02/07/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719483743
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,000.00 02/06/2020 Non-covered Recipient Entity
ACADEMIC ALLICANCE IN DERMATOLOGY INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740101385
Principal investigator 1 Novartis Pharmaceuticals Corporation $59,525.56 02/05/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICAL RESEARCH
A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNRISE No dispute reported 06/30/2026 721489011
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721251067
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721252093
Principal investigator 1 Allergan, Inc. $385.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721253789
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,460.05 01/28/2020 Non-covered Recipient Entity
ACADEMIC ALLICANCE IN DERMATOLOGY INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740101383
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $36,818.80 01/27/2020 Non-covered Recipient Entity
Olympian Clinical Research - South Tampa Office
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 736761455
Principal investigator 1 Janssen Research & Development, LLC $3,962.00 01/27/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719483735
Principal investigator 1 Biogen, Inc. $75,055.89 01/21/2020 Non-covered Recipient Entity
Academic Alliance In Dermatology
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease No dispute reported 06/30/2026 736753655
Principal investigator 1 AbbVie Inc. $17,025.00 01/17/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721145757
Principal investigator 1 AbbVie Inc. $1,000.00 01/16/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721145629
Principal investigator 1 Neurocrine Biosciences, Inc. $6,320.41 01/16/2020 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 749845359
Principal investigator 1 AbbVie Inc. $6,127.63 01/13/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
M16-045 No dispute reported 06/30/2026 721145165
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $69,585.58 01/09/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (TRIAL 405-201-00014) No dispute reported 06/30/2026 748802813
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $82,856.14 01/09/2020 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 748802817